Oramed announced that Diabetes, Obesity, and Metabolism, has published an original article which presents the results of a 12-week multicenter, randomized, placebo-controlled trial assessing the safety and efficacy of multiple active doses of Oramed’s lead drug candidate ORMD-0801 in patients with uncontrolled Type 2 Diabetes on chronic background therapy with Metformin or combination oral therapy. The trial met the primary endpoint of statistically significant reductions of HbA1c from baseline to Week 12. In addition, the treatment doses were safe, well tolerated and not associated with weight gain or hypoglycemia.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORMP: